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Health-related quality of life (HRQoL) in common variable immunodeficiency diseases
(CVID) was evaluated by different tools, which were mainly used to compare different
schedules of immunoglobulins administration in cross-sectional or short-term longitudinal
studies. We assessed the HRQoL and psychological status of CVID patients in a longitudi-
nal study over a 6-year period by a generic, non-disease-specific instrument (SF-36), and by
a General Health Questionnaire (GHQ-12) for the risk of depression/anxiety. At baseline, 96
patients were enrolled. After 1 year, a second assessment was performed on 92 patients
and, after 6 years, a third assessment was performed on 66 patients. Eighteen patients
died during the study time. HRQoL was low, with mental health scales less affected than
physical scales. A decline in the score on SF-36 scales was observed between the first
and the third assessment for the Physical Functioning, Body Pain, General Health, Social
Functioning, and Role-Emotional scales. The General Health scale showed a lower score
in these patients, when compared to patients with other chronic diseases. Approximately
one-third of the patients were at risk of anxiety/depression at all observation times, a per-
centage that reached two thirds of the patients, considering only the group of females.
Over the 6 years of the study, the health condition of 11/66 patients worsened, passing
from “GHQ-negative” to “GHQ-positive”; their score on SF-36 scales also decreased. A
decrement of one point in each of the Physical Functioning, Vitality, Social Functioning, and
Mental Health SF-36 scales increased the risk of developing anxiety/depression from three
to five percent. A negative variation of the Physical Functioning score increased the risk of
psychological distress. In a survival analysis with dichotomized variables, Physical Function-
ing scores<50 were associated with a relative risk (RR) of 4.4, whereas Social Functioning
scores <37.5 were associated with a RR of 10.0. In our study, it was the clinical condition,
as opposed to the different treatment strategies with immunoglobulins, which had a major
role on the deterioration of HRQoL. Moreover, in a quality-of-life evaluation, disorders such
as anxiety/depression should be assessed, as they yet often go unrecognized. Our results
might be helpful in the interpretation of currently available data on quality of life in CVID
patients.
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INTRODUCTION
The health-related quality of life (HRQoL) is a multidimensional
concept that encompasses measurements of physical, psychologi-
cal, and social well-being and assesses the individual’s perception
of the impact of illness on his/her life (1).
Common variable immunodeficiency diseases (CVIDs) rep-
resent a heterogeneous group of rare chronic disorders of the
immune system (2). The prognosis can vary from benign to very
complex conditions (3). There is substantial evidence that the stan-
dard replacement treatment with immunoglobulins prolongs sur-
vival, reduces morbidity, and exerts a positive effect on the patients’
HRQoL (4). Until now, different tools to evaluate HRQoL in CVID
were used mainly to assess the patients’ outcome and satisfaction
related to different treatment choices (i.e., intravenous-IVIG vs.
subcutaneous-SCIG immunoglobulin routes of administration)
(5, 6). However, HRQoL in CVID should be assessed in the frame
of the wide spectrum of the severity of the disease, taking into
consideration the long life course of the disease.
There are several critical reasons to evaluate the available data
on HRQoL in CVID. The absence of a disease-specific question-
naire is a major limitation. Only observational or short-term
longitudinal studies on small cohorts were performed. Differences
in HRQoL were mainly evaluated to compare different treatment
regimens and routes of immunoglobulins administration.
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With such limitations in evaluating quality of life in CVID,
both ourselves and others (7–9) have used generic, non-disease-
specific instruments, such as the Health Status Questionnaire
(Medical Outcome Study 36-Items Short Form, SF-36) and the
General Health Questionnaire (GHQ-12 Items) for the psycho-
logical assessment. All the studies agreed that CVID patients have
a poor quality of life, especially in the physical domain, suffer a lot,
and are at risk of psychological distress.
Because of the long lifetime of the disease, it is possible to
speculate that quality of life in a population affected by a clinical
and immunological heterogeneous disease may vary depending
on age, treatment, clinical conditions, associated diseases, personal
attitude, etc. Thus, it is evident that studies about the HRQoL out-
come in CVID should be extended from a simple assessment to
multimodal and longitudinal assessments and should include the
patients’ reported outcome measures.
The aim of this study was to assess the HRQoL and psycho-
logical status of patients with CVID over a 6-year period, using
SF-36 and GHQ-12 questionnaires. Moreover, we investigated
whether the psychological problems of patients, such as risk of
depression/anxiety, could be associated with their health status.
MATERIALS AND METHODS
STUDY DESIGN
For this observational, longitudinal, cohort study (Figure 1),
performed in a day hospital setting, patients’ participation was
obtained after signing an informed consent. The study was con-
ducted in the period 2008–2013. One hundred twelve CVID
patients were informed and considered eligible for the study. At
basal time (T0), 96 patients were enrolled and 16 patients refused
to participate. After 1 year, at the second assessment (T1) 92 out of
96 patients were evaluated (between T0 and T1 two patients died
and two patients refused to continue the study). After 6 years, 66
out of 92 patients were available for the third assessment (T2).
Between T1 and T2, 12 patients refused to participate and 16
patients died in the 5-year period. At the end of the study, data
for the 66 patients were considered, taking into account all three
observations. At T0, T1, and T2, patients were asked to fill in ques-
tionnaires concerning their health status and the possible presence
of risk for depression and/or anxiety. The severity of disease judged
by the physician (Physician Global Assessment, PhGA) and by the
patient (Patient’s Global Assessment, PtGA) was recorded. The
study protocol was approved by the Ethical Board of the Sapienza,
University of Rome.
PATIENTS
We enrolled 112 patients with CVIDs attending our Reference
Center for Primary Immune Deficiencies. Patients were diagnosed
according to the ESID/PAGID criteria for CVIDs (10), based on
IgG <500 mg/dL, IgA 2 SD below age-specific reference range,
age onset >4 years, poor response to vaccines, and exclusion of
other causes of hypogammaglobulinemia. No genetic causes of
CVID were identified in this cohort. A detailed set of data was
available, since all patients with a diagnosis of CVID have been
regularly followed up in our center according to the Italian guide-
lines (www.aieop.org); their clinical and immunological data have
been collected regularly in a national database, once a year. The
FIGURE 1 | Study flow chart. The number of patients analyzed at baseline
(T0), after 1 year (T1), and after 6 years (T2). The number of patients who
refused to continue the study and the number of patients who died during
the study time is shown.
dataset included age, date of CVID diagnosis, immunological data,
including lymphocyte subsets and serum IgG, IgA, and IgM levels
determined every 3 months, clinical manifestations, route, doses,
and intervals of Ig replacement, and occurrence of adverse reac-
tions. Route, dosage, and interval of Ig replacement were recorded
once a month. At T0, 84 patients were on replacement therapy
with IVIG and 12 with SCIG. Between T0 and T2, 6/66 patients
shifted from IVIG to SCIG. High-resolution chest computerized
tomography (HRCT) scans was performed once in every 4 years
in all patients according to national guidelines. All patients have
been on IVIG or SCIG replacement for at least 5 years.
QUESTIONNAIRES
We used validated tools: SF-36, GHQ-12, and PGA questionnaires.
SF-36
Despite the fact that it was designed as a generic health status indi-
cator for use in population surveys and health policy evaluation
studies, the SF-36 can also be used as an outcome measure (11,
12). The SF-36 includes 36 items in a Likert-type or forced-choice
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format, intended for measuring the following eight dimensions:
physical functioning (PF, limitations in performing physical activ-
ities such as bathing or dressing), role-physical (RP, limitations in
work and other daily activities as a consequence of physical health),
bodily pain (BP, how severe and limiting pain is), general health
(GH, how general personal health is perceived by the patient),
vitality (VT, feeling tired and worn out vs. feeling energetic),
social functioning (SF, interference with regular social activities
because of physical or emotional problems), role-emotional (RE,
limitations in work and other daily activities as a consequence of
emotional problems), and mental health (MH, feeling nervous and
depressed vs. peaceful, happy, and calm). Scores for each domain
ranged from 0 to 100, with higher scores indicating better health.
Two additional summary measures, the physical component sum-
mary (PCS) and mental component scores (MCS), cross-culturally
validated in the framework of the International Quality of Life
Assessment project for the Italian version of the SF-36, were also
obtained.
GHQ-12
The GHQ-12 is a self-administered, 12-item questionnaire,
designed to measure psychological distress and to detect current
non-psychotic, psychiatric disorders, such as depression and anx-
iety (13, 14). Answers are given on a 4-point scale; for instance,
the item “in the last weeks, did you feel under strain?” allows for
the following answers: “no,” “not more than usual,” “more than
usual,” and “much more than usual.” When scored with the binary
method (0–0–1–1), the GHQ-12 can be used as a screening tool to
detect minor non-psychotic, psychiatric disorders, yielding final
scores that range from 0 to 12. Operationally, patients scoring 4 or
more were considered as “GHQ-positive” (GHQ+).
PGA
For each patient, an overall clinical severity evaluation of the dis-
ease was given by the provider and by the patient him/herself. The
PhGA and the PtGA consisted of the following questions respec-
tively: “In your opinion, compared to other patients with the same
condition, how severe is the disease of patient X?” and “In your
experience, how severe is your disease?” Answers were given on a
5-point scale: “very mild,” “mild,” “moderate,” “severe,” and “very
severe.” For the purpose of statistical analysis, “very mild”/“mild”
were considered as low severity and “severe”/”very severe” as high
severity, and were grouped. The same physician at T0, T1, and T2
recorded her evaluation at the end of the visit. Patients recorded
his/her evaluation after the completion of the questionnaires.
STATISTICS
In the first part, for descriptive analyses and comparisons among
groups, we used t -test for independent samples and ANOVA for
the comparison of mean values, due to the samples’ size. Chi-
squared test was also used for the comparison of percentages.
For the 66 patients present in each observation, paired tests were
used. In the second part, we performed a logistic regression analy-
sis to assess the independent role of SF-36 scales on GHQ-12
deterioration over time. In the last part, in order to investigate fac-
tors predicting mortality, survival analysis was performed, both
through Kaplan–Meier curves and Cox regression analysis. All
analyses were performed using the Stata version 11 (Stata Corp,
College Station, TX, USA).
RESULTS
The study design flow chart on CVID patients enrolled in the
cohort study is shown in Figure 1. One hundred twelve patients
were enrolled; 96 patients accepted to participate in the study
[M/F: 50/46; mean age: 48.2± 17.0 years old (range 14–85);
mean time of disease since diagnosis: 10.7 years (range 5–36)];
92 patients [M/F: 47/45; mean age: 49± 4.9 years old (range
15–86)] completed the second assessment. Sixty-six patients
[M/F: 32/34; mean age: 50± 5.7 years old (range 20–76)] com-
pleted the T0, T1, and T2 assessments. Thirty patients refused
to participate (16 at T0, 2 at T1, and 12 at T2). Eighteen
patients [M/F: 9/9; mean age: 62.9± 14.7 years old (range 39–88)]
died in the 6-year period. Causes of death were: gastrointesti-
nal cancer (5 patients), lymphoproliferative diseases (5 patients),
chronic lung disease (CLD) (2 patients), cirrhosis (1 patient), and
granulomatosis (5 patients).
DESCRIPTIVE ANALYSES
Patients’ characteristics at baseline and comparison between
SF-36 in CVID and in other chronic diseases
At baseline (T0), the characteristics of patients were those reported
in our study published in 2012 (7). A summary of our previous
data on HRQoL is reported in Table 1. Being female, older, and
affected by CLD and chronic diarrhea proved to be major risk
factors leading to a poor quality of life. The basal mean scores for
SF-36 scales were also compared to those reported (12) on patients
affected by other chronic diseases (Table 2). HRQoL was lower
than that reported in generally healthy population, with men-
tal health scales less affected than physical scales. In CVID, better
scores for PF,BP,VT,SF,RE,and MH scales were observed,while RP
and GH scales showed a lower score in comparison to patients with
all other disease entities, with the exception of patients affected
by heart failures who showed the lowest scores. The different age
range of patients in each group (older in cancer, younger in CVID)
has a significant effect on profiles of SF-36 average scores. There-
fore, one must be cautious in the interpretation of differences in
SF-36 scores between pathologies: they cannot be entirely attrib-
uted to the “pure” effect of the disease. This consideration is even
more valid in the longitudinal study.
Longitudinal variation of SF-36
Longitudinal variations in SF-36 scores were observed over the
whole sample, as well as over the subsample of 66 patients attend-
ing all three sequential assessments. The scores observed con-
sidering the SF-36 mean values in the 66 patients, who were
followed at all three points of observation times, are shown in
Figure 2. Differences in the scores of SF-36 scales between T0
and T2 are statistically significant for the following scales: PF
(p= 0.03), BP (p= 0.05), GH (p= 0.02), SF (p= 0.002), and RE
(p= 0.03). However, we should consider the age dependence of all
scales, especially because patients at T2 were 6 years older than at
T0. Moreover, we found no differences in HRQoL scales between
patients on replacement with IVIG and SCIG.
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Table 1 | SF-36 mean values (SD) and clinical characteristics of CVID patients.
n PF RP BP GH VT SF RE MH PCS MCS
All 96 72 (25) 47 (42) 67 (26) 39 (24) 55 (22) 69 (22) 68 (40) 66 (20) 40 (12) 43 (12)
Gender
Male 50 78 (24) 59 (41) 73 (25) 44 (27) 62 (20) 72 (23) 74 (38) 69 (20) 43 (12) 45 (12)
Female 46 66 (25) 34 (40) 60 (26) 34 (20) 47 (21) 66 (21) 62 (42) 63 (19) 36 (11) 42 (12)
Age
<50 years 52 84 (19) 56 (42) 74 (26) 43 (27) 59 (21) 69 (24) 79 (33) 68 (19) 44 (12) 44 (12)
≥50 years 44 58 (25) 39 (40) 59 (25) 35 (21) 51 (22) 70 (20) 55 (43) 64 (21) 34 (11) 43 (13)
Duration of disease
≤8 years 47 73 (28) 49 (42) 69 (28) 42 (23) 55 (20) 68 (24) 72 (38) 63 (20) 41 (13) 43 (13)
>8 years 46 71 (23) 44 (42) 65 (26) 37 (27) 56 (24) 69 (21) 64 (42) 68 (20) 39 (12) 44 (12)
Co-morbidities
CLD 62 70 (25) 41 (41) 63 (26) 37 (23) 54 (23) 65 (23) 60 (41) 63 (21) 38 (12) 41 (13)
Sinusitis 48 73 (25) 44 (43) 66 (28) 36 (23) 54 (22) 68 (22) 65 (42) 65 (22) 39 (12) 42 (13)
Diarrhea 42 65 (26) 37 (40) 60 (29) 34 (24) 51 (23) 65 (24) 54 (41) 63 (22) 36 (12) 41 (13)
SF-36 scales: PF, physical functioning; RP, role-physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role-emotional; MH, mental health;
PCS, physical component summary; MCS, mental component summary; CLD, chronic lung disease; CVID, common variable immunodeficiency.
Bold – p<0.05.
Totals may vary because of missing values.
Table 2 | Mean values of SF-36 scales for CVID patients compared with healthy subjects and with patients with different chronic diseases in Italy.
N PF RP BP GH VT SF RE MH
Healthy subjects 608 97.3 94.3 89.2 80.2 72.2 86.4 88.0 75.8
Diabetes 98 62.9 59.7 59.8 43.6 47.6 66.9 57.6 53.4
Heart failure 129 49.5 43.1 47.6 35.4 38.3 54.8 46.3 46.6
Cancer 34 60.6 62.4 57.0 44.9 48.3 64.1 58.6 49.9
Chronic obstructive pulmonary disease 188 58.7 49.5 52.0 41.5 45.8 62.6 55.8 53.5
Mental disorders 180 65.4 49.5 51.9 44.7 40.9 55.0 43.7 42.0
CVID 96 72.4 47.3 67.2 39.3 55.2 69.5 68.3 66.3
SF-36 Scales: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), Mental
Health (MH). SF-36 values for Italian diseases (12).
GHQ assessment and PtGA/PhGA
GHQ-12 assessment showed that more than 35% of the patients
were at risk of anxiety and depression (GHQ-positive) at all
observation times (Table 3). This percentage was increased to
about 70% in females. The disease severity perception graded by
patients and by physicians at the three points of observation is
reported in Table 3. Differences between the perception of patients
and physicians were more evident at T2, with higher percent-
age of low severity grade reported by physicians. As expected,
PhGA was greater in GHQ-positive patients. Twenty-five per-
cent of GHQ-positive patients considered their disease severity
as high.
The 15 patients who were permanently GHQ-positive at all
observations had constantly low mean values of scores on SF-
36 scales. Patients with a highly severe perception of the disease
(PtGA) and patients who were judged as seriously affected by the
physicians (PhGA) reported a lower health status with respect to
the others.
GENERAL HEALTH QUESTIONNAIRE DATA AND VARIATIONS OF MEAN
VALUES IN SPECIFIC SF-36 SCALES
To analyze the relationship between SF-36 and GHQ-12 data, vari-
ation in GHQ status between T0 and T2 were coded as 1 when
GHQ passed from 0 to 1 (GHQ-worsened) and as 0 in all other
instances (GHQ-stable/improved). Changes in SF-36 scales were
recorded as absolute differences between values at T0 at T2. Aver-
age variation in SF-36 scores was then compared between the
group of GHQ-worsened and GHQ-stable/improved. The SF-36
scales showing variations significantly different in the two groups
(GHQ-worsened and GHQ-stable/improved) were selected.
Over the 6-year observational period, the general health condi-
tion of 11/66 patients worsened, passing from “GHQ-negative” to
“GHQ-positive” status, i.e., showing symptoms of psychological
distress.
These patients also registered a negative score variation on
SF-36 scales: Physical Functioning, Vitality, Social Functioning,
and Mental Health. In a logistic regression, controlled for age
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FIGURE 2 | Profile of the mean values for each scale of SF-36 for
the group of 66 CVID patients observed at different times (T0,
black column;T1, pale-gray column;T2, gray column). SF-36 Scales:
Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General
Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE),
Mental Health (MH), Physical component summary (PCS), and
Mental component summary (MCS). *Significant p-values between
T0 and T2.
Table 3 | Gender, GHQ status, and disease severity reported by
patients and by physicians at each assessment (numbers and
percentages).
All n.96 (T0) (%) n.92 (T1) (%) n.66 (T2) (%)
Sex Males 52 51 52
Females 48 49 48
GHQ+ 36 39 37
GHQ+ Males 28 23 33
Females 72 77 67
PtGA Low 27 17 38
Moderate 49 49 40
High 24 33 22
PhGA Low 17 16 47
Moderate 50 51 39
High 33 33 14
PtGA, Patient Global Assessment; PhGA, Physician Global Assessment.
GHQ, General Health Questionnaire; GHQ+, GHQ-positive/“cases” or GHQ ≥4.
and gender, we noticed that a decrement of 1 point in each
of the four mentioned scales increases the risk of developing
anxiety/depression from 3 to 5% (Table 4). Thus, the GHQ-12
and SF-36 deteriorations were strictly linked. To convey an idea
of the magnitude of the effect, we considered the cumulative
observed variation of the Physical Functioning scale (PF) over
the follow-up period: 10 points. The odds ratio of 1.05 means that
a patient affected by the average negative variation of PF has an
increased risk of 5% per year of psychological distress. Also VT,
SF, and MH subscales were strongly influenced by GHQ status
(Figure 3).
Table 4 | Odd ratio (OR) and p-values for SF-36 scales for “changes” in
GHQ-12 status (from negative to positive).
SF-36 scale OR p-value
PF 1.05 (1.01–1.06) 0.012
VT 1.04 (1.01–1.05) 0.008
SF 1.03 (1.01–1.06) 0.024
MH 1.04 (1.01–1.07) 0.03
IMMUNOLOGICAL DATA AND HRQoL
In CVID,we have previously identified (15) a severe clinical pheno-
type, characterized by low IgA level (<7 mg/dL) and low switched
memory B cells, confirming previous observations showing that
the loss of function of memory B cells seems to represent the major
cause of CVID-associated clinical conditions (16). Moreover, clin-
ical improvement of CVID was observed in patients receiving
high Ig dosages, >600 mg/kg/months (17, 18). These dosages
might allow to keep IgG trough levels >600–800 mg/dL. We then
grouped our CVID cohort on the basis of three defined parameters:
IgA >7 mg/dL, IgG trough levels >600 mg/dL, switched memory
>2%. At T0, 67% of the patients had IgA levels <7; 50% had
switched memory B cells <2%; 61% had IgG levels >600 mg/dL
(a percentage ranging from 14 to 26 has missing information on
these parameters).
The analysis of the mean values on SF-36 scales in patients
with or without each defined parameter showed no statistically
significant differences among groups.
LOW HRQoL WAS PREDICTIVE OF MORTALITY
Patients’ mortality during the follow-up was registered with exact
date of death. According to this outcome, patients at T0 were
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FIGURE 3 | Mean values for each scale of SF-36 for the group of 66 CVID
patients observed at different times (T0,T1,T2), GHQ status (T0 andT2)
and PtGA and PhGA assessments. (A) GHQ at T0: black column
GHQ-negative; gray column: GHQ-positive. (B) GHQ at T2: black column
GHQ-negative; gray column: GHQ-positive. (C) PtGA (black column: very
mild/mild; pale-gray column: moderate; gray column: severe/very severe).
(D) PhGA (black column: very mild/mild; pale-gray column: moderate; gray
column: severe/very severe).
divided into two groups: survivors vs. deceased. Cox Survival
analysis was performed, introducing as covariates the SF-36 scales
that showed marked differences between survivors and deceased
at T0. Age and gender were also included in the analysis in order
to estimate the role of HRQoL in predicting mortality, as adjusted
by these two variables. For the SF-36 scales independently pre-
dictive of mortality, we operated a dichotomization of values,
indicating “at-risk” and “not at-risk” patients. The cut-off val-
ues were selected observationally based on points of disruption
in the trend of number of death over SF-36 scores. For SF-36
scales predictive of mortality, we graphed the two groups (“at-
risk” and “not at-risk”) with Kaplan–Meier survival curves, whose
significance was verified by Log-rank test. A new Cox survival
analysis with SF-36 scales dichotomized was produced, in order
to assess the specific risk of death for the patients that scored
under the cut-off at T0. The most evident difference between
the two groups (Table 5) is, not surprisingly, in terms of age:
survivors are significantly younger than deceased patients. How-
ever, score values of Physical and Social Functioning as well as
Role-Emotional at T0 seem to be remarkably reduced for patients
that died during the study time. This result was partially con-
firmed when adjusted by age: except for the Role-Emotional,
which has no age-independent effect on mortality, both Physi-
cal and Social Functioning score values maintain their significant
predictive power.
The relative risk (RR) of death associated with PF and SF scales
is 0.98 and 0.97, respectively, meaning that each point increase
in Physical and Social Functioning scores, independently of age,
reduced the risk of death by 2% and 3%. The two predictive scales
(PF and SF) were then dichotomized based on the observed point
of disruption in the trend of number of deaths per different scores
of PF and SF. More specifically, a cut-off value of 50 was selected
for PF and a value of 37.5 for SF. People with values higher than the
cut-off were classified as “not at-risk,” compared to the “at-risk”
below the cut-off. In a survival analysis with these dichotomized
variables, PF scores <50 were associated with a RR of 4.4 (CI:
1.7–11.8, p< 0.03) and SF scores <37.5 determined a RR of 10.0
(CI: 2.6–37.9, p< 0.001). In other words, all other variables being
equal, patients with scores below the cut-off in Physical Function-
ing have 4.4 times the risk of dying than patients with higher scores;
the same risk is 10 times higher for patients under the cut-off in
social functioning. Figures 4A,B compare survival rates over the
follow-up period, between “at-risk” and “not at-risk” patients as
classified by T0 for PF/SF scores. The difference is extremely sig-
nificant with the “at-risk” group survival curve always below the
“not at-risk”curve (Log-rank test<0.0001). The median value was
approached in both the “at-risk” groups, meaning that half of the
patients have died at 48 months (SF) and 60 months (PF), whereas,
the percentage of death in the “not at-risk” groups is lower than
25% at the end of the observation period (72 months).
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Table 5 | Characteristics of survival and deceased patients.
Characteristics All
patients,
N =96
Survived
patients,
N =78
Deceased
patients,
N =18
p-Value
SF-36 scores, mean (SD)
PCS 39.8 (12.4) 40.8 (12.5) 35.5 (10.9) 0.06
MCS 43.4 (12.2) 44.0 (12.1) 41.0 (12.9) 0.18
Physical Functioning 72.4 (25.4) 76.9 (23.4) 53.8 (25.8) 0.001
Role-Physical 47.3 (42.3) 50.3 (42.4) 34.7 (40.3) 0.08
Body Pain 67.1 (26.5) 67.5 (26.9) 65.9 (25.9) 0.41
General Health 39.3 (24.5) 40.1 (25.3) 36.0 (21.2) 0.27
Vitality 55.2 (21.8) 56.8 (21.1) 48.6 (23.8) 0.08
Social Functioning 69.5 (22.2) 71.5 (21.6) 61.1 (23.4) 0.04
Role-Emotional 68.3 (39.8) 73.1 (37.3) 48.1 (44.6) 0.008
Mental Health 66.3 (19.9) 67.6 (19.1) 60.7 (22.6) 0.09
Age, mean years (SD) 48.2 (17.0) 44.8 (15.7) 62.9 (14.7) 0.0001
Gender, men% 52.2 52.6 50.0 0.84
GHQ, cases% 26.6 28.6 27.7 0.36
IgA, >7 mg/dL% 32.9 33.3 30.0 0.83
IgG, >600 mg/dL% 61.0 63.9 40.0 0.5
SW mem, >2% 50.0 50.8 44.4 0.72
DISCUSSION
Patient reported outcome measures in clinical practice, in par-
ticular, those evaluating HRQoL (19), have been proposed as a
means of facilitating doctor–patient communication, uncovering
patients’ problems, as well as monitoring disease or treatment, and
as a screening for functional problems (20, 21). In a previous study
on HRQoL performed in our cohort of CVID patients, we showed
(7) a low HRQoL in particular in physical domains: the Role-
Physical and the General Health scales of the SF-36 questionnaire.
Moreover, we showed that being female, older, and GHQ-positive
proved to be major risk factors associated with a poor health sta-
tus. Here, we extended the study time over a 6-year period. To our
knowledge, this is the first longitudinal assessment of HRQoL in
adult CVID patients. We confirmed that HRQoL was lower than
that reported in generally healthy population with mental health
scales less affected than physical scales. Moreover, Physical Role
and General Health scales showed the worse scores at all obser-
vational times and were lower than those reported in patients
with other chronic disease entities (12), with the exception of
patients affected by heart failures. Moreover, we showed that about
one-third of patients were at risk of anxiety/depression at all obser-
vation times, a percentage that reached two-thirds of patients,
considering only the group of females. The crucial role of anxi-
ety/depression symptoms on HRQoL has been proven recently also
in a pediatric population affected by primary immunodeficien-
cies, where the disease was less likely to affect physical functioning
than psychosocial functioning (22). Patients tested continuously
that GHQ-positive had a perception of the disease as severe and
recorded low mean values of all SF-36 scales. Thus, the GHQ-12
and SF-36 deteriorations were strictly linked. However, it is impos-
sible to verify which might be the primum movens. Since patients
with a decrease of the Physical Functioning, the worse SF-36 scale
in CVID, increased their risk of psychological distress about 50%
FIGURE 4 | Survival rates for CVID patients (“at-risk” vs. “not at-risk”)
considering SF-36 scales: Physical Functioning, cut-off at 50 (A) and
Social Functioning cut-off at 37.5 (B). (dico: dichotomized).
during the observational time, it is possible to hypothesize that
the disease might be the major cause of depression/anxiety. Our
data on HRQoL confirmed the data reported 10 years ago in the
first multidimensional assessment on HRQoL in CVID (23) and
more recently in a survey run by IPOPI (4). However, SF-36 scales
showed less severe defects than those previously reported, possibly
because of the over-representation of females in both studies. All
studies recognized limitations in work and other daily activities
as a result of declined physical health and general health. HRQoL
measures ensure that treatment and evaluations are focused on
the patient rather than on the disease, and may be used as a way of
capturing the personal and social context of patients and linking it
to the classical clinical view of the disease. However, while HRQoL
measures are now quite commonly included in the protocols of
randomized, controlled clinical trials and other clinical studies,
their use in routine clinical practice is still quite limited; they were
never used in combination with other questionnaires, limiting the
www.frontiersin.org November 2014 | Volume 5 | Article 605 | 7
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possibility to identify correct measures of intervention. In fact,
our experience in the evaluation of the HRQoL in a day hospital
setting for CVID patients, confirmed what has been observed in
other diseases, namely that GHQ-positive patients (with minor
psychiatric, non-psychotic diseases such as depression or anxi-
ety) suffer a lot (13). Thus, in the comprehensive evaluation of the
patients’ status, their psychological condition and disorders such as
anxiety/depression should be evaluated in a global HRQoL assess-
ment as they yet often go unrecognized. Counseling can be useful
in GHQ-positive patients, since an improvement of GHQ status
might lead to a better HRQoL. On the other hand, an improvement
in HRQoL can be associated with improvement in psychologi-
cal well-being. Our results might be helpful in the interpretation
of data currently available on quality of life in CVID patients
receiving different immunoglobulin treatment options. A recent
study from IPOPI (4) reported that most patients were satisfied
with their current therapy. Significant differences in satisfaction
were seen when comparing SCIG with IVIG administration; SCIG
respondents were more satisfied with treatment than IVIG respon-
dents. Since we have shown that the perception of disease severity
was linked to the GHQ status and that GHQ-positive patients will
perceive their disease as more severe, without a parallel assessment
of the psychological status of patients receiving SCIG or IVIG, it
might be difficult to attribute an advantage to a treatment modal-
ity vs. another. Moreover, as the authors claimed, the results of
the survey done on patients affiliated to the IPOPI, might not rep-
resent all people with primary immune deficiencies treated with
immunoglobulin therapy. Despite this limitation, their data indi-
cated that the primary immunodeficiency impacted on quality of
life, also taking into account the favorable effect of immunoglob-
ulin treatment. In our study, the clinical condition, as opposed
to the different treatment strategies with immunoglobulins, had
a major role on the deterioration of HRQoL. Values of Physical
and Social Functioning as well as Role-Emotional scales of SF-
36 at T0 were remarkably reduced for patients that died during
the study time. Even if survivors were significantly younger than
deceased patients,with the exception of the Role-Emotional,which
has no age-independent effect on mortality, both Physical and
Social Functioning maintained their significant predictive power.
The RR of death for PF and SF was 0.98 and 0.97, respectively,
meaning that each point increase in PF and SF, independently
of age reduces the risk of death by 2 and 3%, respectively. We
have already shown (24) that malignancies are the major cause of
death in patients with adult onset CVID: the high rate of mortality
(about 20% in a 40-year follow-up) was similar to that reported in
a study run in the United States of America over a similar period
of follow-up (25). The high rate of mortality observed here fur-
ther confirmed the need to focus our attention on early diagnosis
of non-lymphoid and lymphoid cancers that influence lives and
HRQoL in CVID. Monitoring health status in long-term longi-
tudinal studies with generic tools, such as SF-36 and GHQ-12,
may provide information about clinical status, therapy efficacy,
and eventually a modification in physical or mental status. It is
relevant to consider here the specificities of each area of the SF-36
health status and the GHQ-12 assessments, taking into consid-
eration any effort to reduce the physical burden of the disease.
However, a major limitation in the assessment of HRQoL in CVID
is still the absence of a disease-specific questionnaire available to
monitor quality of life in many other diseases. We are now devel-
oping and validating a CVID-disease-specific questionnaire on
HRQoL necessary to complement evidence-based guidelines and
policies.
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